Physician profile
Sandra Kay Schuldheisz
NPI 1194798934
$224,580.93
in general payments reported to CMS, 2019-2025
27 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $30K · 2021: $31K · 2022: $27K · 2023: $35K · 2024: $29K · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Education: $9,180 · Travel and Lodging: $4,943 · Food and Beverage: $4,656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $56,666.25 |
| Education | $9,179.98 |
| Travel and Lodging | $4,942.83 |
| Food and Beverage | $4,655.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $86,603.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sunovion Pharmaceuticals INC. | $45,414.29 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34,323.03 | 2019-2024 | Ofev, Spiriva Respimat |
| Mylan Specialty L.P. | $34,241.47 | 2022-2024 | Yupelri, Yupelri |
| Intuitive Surgical, INC. | $10,378.48 | 2023-2025 | Da Vinci Surgical System |
| Viatris Specialty LLC | $9,755.98 | 2025 | Yupelri |
| Grifols USA, LLC | $1,246.30 | 2019-2025 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals Lp | $555.20 | 2019-2025 | Tezspire, Airsupra, Breztri |
| Jazz Pharmaceuticals INC. | $517.57 | 2019-2025 | |
| Harmony Biosciences LLC | $303.61 | 2020-2024 | Wakix |
| Amgen INC. | $303.50 | 2024-2025 | Tezspire |
| Ucb, INC. | $197.31 | 2019-2023 | |
| Inspire Medical Systems, INC. | $188.25 | 2024-2025 | Inspire |
| Verona Pharma, INC. | $133.32 | 2025 | Ohtuvayre |
| Erbe USA INC | $100.00 | 2025 | Erbecryo2 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $70.74 | 2020-2023 | Keytruda |
| Idorsia Pharmaceuticals US INC | $45.17 | 2023 | Quviviq |
| Circassia INC. | $33.90 | 2019 | |
| Mallinckrodt Enterprises LLC | $25.41 | 2019 | |
| United Therapeutics Corporation | $22.78 | 2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.52 | 2023 | Lifevest |
| Paratek Pharmaceuticals, INC. | $20.18 | 2025 | Nuzyra |
| Philips North America LLC | $19.95 | 2020 | |
| Optinose US, INC. | $16.17 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.17 | 2022 | |
| Covis Pharma Gmbh | $14.58 | 2022 | |
| Baxter Healthcare | $13.79 | 2025 | Hillrom - Vest System Model 105 Home Care |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Schuldheisz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.